The safety and efficacy of trabectedin for the treatment of liposarcoma or leiomyosarcoma

被引：6
|
作者：
Saponara, Maristella [1 ,2 ]
Stacchiotti, Silvia [2 ]
Gronchi, Alessandro [3 ]
机构：
[1] Univ Bologna, St Orsola Malpighi Hosp, Dept Specialized Expt & Diagnost Med, Via Massarenti 9, I-40138 Bologna, Italy
[2] Fdn IRCCS Ist Nazl Tumori, Dept Canc Med, Milan, Italy
[3] Fdn IRCCS Ist Nazl Tumori, Dept Surg, Milan, Italy
来源：
EXPERT REVIEW OF ANTICANCER THERAPY | 2016年 / 16卷 / 05期
关键词：
Trabectedin; liposarcoma; leiomyosarcoma; L-Sarcoma; mechanism of action; myxoid liposarcoma; duration of treatment; second line options; combination therapy; histology driven therapy; ADVANCED SOFT-TISSUE; RANDOMIZED PHASE-II; DOXORUBICIN PLUS IFOSFAMIDE; CONTINUOUS INTRAVENOUS-INFUSION; COLONY-STIMULATING FACTOR; TUMOR RESPONSE ASSESSMENT; HIGH-DOSE DOXORUBICIN; EUROPEAN-ORGANIZATION; 1ST-LINE TREATMENT; PROGNOSTIC-FACTORS;
D O I：
10.1080/14737140.2016.1174582
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
The improvement of molecular knowledge has highlighted the prognostic and predictive significance of histological subtypes in soft tissue sarcoma (STS). Here we focus on trabectedin, a drug characterized by a unique action combining cytotoxic and target effects. We retraced its main steps of development and peculiarities regarding mechanism of action, efficacy and safety especially towards liposarcoma and leiomyosarcoma and we compared it against the leading therapeutic alternatives with the aim to answer some practical questions such as: who and when to treat with trabectedin? For how long? What is the safety profile? When should trabectedin be preferred to other treatment options? Finally, we provided our viewpoint on how the scenario might evolve in the coming years particularly about the 'place' of trabectedin in the therapeutic algorithm and its future possible use in combination with other agents in order to achieve even more satisfactory results in STS management.
引用
收藏
页码：473 / 484
页数：12
相关论文
共 50 条
  • [31] Final overall survival (OS) analysis of the randomized phase 3 study of trabectedin (T) or dacarbazine (D) for the treatment of patients (pts) with advanced leiomyosarcoma (LMS) or liposarcoma (LPS)
    Patel, S.
    Von Mehren, M.
    Reed, D.
    Agulnik, M.
    Kaiser, P.
    Charlson, J.
    Kraft, A.
    Hamm, J.
    Karnad, A.
    Ryan, C.
    Rushing, D.
    Meyer, C.
    Khokhar, N. Z.
    McCarthy, S.
    Park, Y. C.
    Knoblauch, R. E.
    Parekh, T. V.
    Maki, R. G.
    Demetri, G. D.
    EUROPEAN JOURNAL OF CANCER, 2015, 51 : S689 - S689
  • [32] Efficacy and safety of eribulin plus anlotinib and camrelizumab in advanced or metastatic retroperitoneal liposarcoma (RLPS) or leiomyosarcoma (RLMS): A singlecenter retrospective cohort study
    Wu, J.
    Hao, C.
    Jia, W.
    Lv, A.
    Qiu, H.
    Li, C.
    Liu, B.
    Liu, Q.
    Liu, D.
    Wang, Z.
    Sun, R.
    Wang, X.
    Xue, G.
    Tian, X.
    ANNALS OF ONCOLOGY, 2023, 34 : S1043 - S1043
  • [33] Trabectedin for metastatic liposarcoma and leiomyosarcoma: Comparison of real-world experience in an Australian sarcoma specialist center to pivotal clinical trial results
    Zhou, Deborah Di-Xin
    King, Daniel
    Thomson, Katie
    Grimison, Peter
    ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY, 2022, 18 (05) : E526 - E528
  • [34] Randomized phase II study of trabectedin in patients with liposarcoma and leiomyosarcoma (L-sarcomas) after failure of prior anthracylines (A) and ifosfamide (I)
    Morgan, J. A.
    Le Cesne, A.
    Chawla, S.
    Von Mehren, M.
    Schuetze, S.
    Casali, P. G.
    Nieto, A.
    Elsayed, Y.
    Izquierdo, M. A.
    Demetri, G. D.
    JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (18)
  • [35] TRAbectedin in adVanced rEtroperitoneal well differentiated/ dedifferentiated Liposarcoma and Leiomyosarcoma (TRAVELL): results of a phase II study from the Italian Sarcoma Group
    Fabbroni, C.
    Grignani, G.
    Vincenzi, B.
    Fumagalli, E.
    De Pas, T. M.
    Mazzocca, A.
    Brunello, A.
    Baldi, G. G.
    Boglione, A.
    Fatigoni, S.
    Berruti, A.
    Giordano, M.
    Marrari, A.
    Tos, A. P. Dei
    Alberton, A. S.
    Aliberti, S.
    Carlucci, L.
    Rulli, E.
    Casali, P. G.
    Sanfilippo, R.
    ESMO OPEN, 2024, 9 (08)
  • [36] Genomic Evolutionary Patterns of Leiomyosarcoma and Liposarcoma
    Amin-Mansour, Ali
    George, Suzanne
    Sioletic, Stefano
    Carter, Scott L.
    Rosenberg, Mara
    Taylor-Weiner, Amaro
    Stewart, Chip
    Chevalier, Aaron
    Seepo, Sara
    Tracy, Adam
    Getz, Gad
    Hornick, Jason L.
    Nucci, Marisa R.
    Quade, Bradley
    Demetri, George D.
    Raut, Chandrajit P.
    Garraway, Levi A.
    Van Allen, Eliezer M.
    Wagner, Andrew J.
    CLINICAL CANCER RESEARCH, 2019, 25 (16) : 5135 - 5142
  • [37] Safely combining trabectedin with radiotherapy to treat myxoid liposarcoma
    Chen, Mark
    Kirsch, David G.
    ECLINICALMEDICINE, 2019, 9 : 5 - 6
  • [38] Safety and efficacy of trabectedin when administered in the inpatient versus outpatient setting: Clinical considerations for outpatient administration of trabectedin
    Jones, Robin L.
    Maki, Robert G.
    Patel, Shreyaskumar R.
    Wang, George
    McGowan, Tracy A.
    Shalaby, Waleed S.
    Knoblauch, Roland E.
    von Mehren, Margaret
    Demetri, George D.
    CANCER, 2019, 125 (24) : 4435 - 4441
  • [39] Treatment results of trabectedin (T) in patients (pts) with myxoid-round cell liposarcoma (MRCL)
    Kawai, Akira
    Araki, Nobuhito
    Sugiura, Hideshi
    Ueda, Takafumi
    Yonemoto, Tsukasa
    Takahashi, Mitsuru
    Morioka, Hideo
    Hiraga, Hiroaki
    Hiruma, Toru
    Takahashi, Shunji
    ANNALS OF ONCOLOGY, 2015, 26 : 104 - 104
  • [40] Stable disease in a patient with metastatic leiomyosarcoma treated with trabectedin
    Tavella, Ketty
    Villanucci, Alessandro
    Vannini, Laura
    Lavacchi, Daniele
    Montelatici, Silvia
    Amunni, Gianni
    Mazzei, Teresita
    ANTI-CANCER DRUGS, 2017, 28 (04) : 465 - 468
12345